Goldman Sachs’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.42M | Sell |
174,901
-654,516
| -79% | -$29M | ﹤0.01% | 3204 |
|
|
2025
Q4 | $34.2M | Buy |
829,417
+282,907
| +52% | +$11.3M | ﹤0.01% | 1828 |
|
|
2025
Q3 | $21.2M | Buy |
546,510
+162,842
| +42% | +$5.29M | ﹤0.01% | 2204 |
|
|
2025
Q2 | $10.6M | Buy |
383,668
+227,340
| +145% | +$5.79M | ﹤0.01% | 2704 |
|
|
2025
Q1 | $3.47M | Sell |
156,328
-54,859
| -26% | -$1.13M | ﹤0.01% | 3701 |
|
|
2024
Q4 | $4.18M | Sell |
211,187
-297,186
| -58% | -$6.78M | ﹤0.01% | 3630 |
|
|
2024
Q3 | $12.7M | Buy |
+508,373
| New | +$12.4M | ﹤0.01% | 2480 |
|
|
2024
Q2 | – | Sell |
-760,107
| Closed | -$15M | – | 5806 |
|
|
2024
Q1 | $15M | Sell |
760,107
-149,105
| -16% | -$2.91M | ﹤0.01% | 2091 |
|
|
2023
Q4 | $15.9M | Buy |
909,212
+43,430
| +5% | +$714K | ﹤0.01% | 2117 |
|
|
2023
Q3 | $15M | Buy |
865,782
+494,264
| +133% | +$8.33M | ﹤0.01% | 2032 |
|
|
2023
Q2 | $5.23M | Sell |
371,518
-50,415
| -12% | -$675K | ﹤0.01% | 3067 |
|
|
2023
Q1 | $4.54M | Sell |
421,933
-593,975
| -58% | -$7.83M | ﹤0.01% | 3155 |
|
|
2022
Q4 | $15.2M | Buy |
1,015,908
+110,640
| +12% | +$1.61M | ﹤0.01% | 2199 |
|
|
2022
Q3 | $11.6M | Buy |
905,268
+271,364
| +43% | +$3.09M | ﹤0.01% | 2370 |
|
|
2022
Q2 | $6.14M | Sell |
633,904
-302,700
| -32% | -$2.82M | ﹤0.01% | 2942 |
|
|
2022
Q1 | $9.31M | Buy |
936,604
+357,387
| +62% | +$3.79M | ﹤0.01% | 2767 |
|
|
2021
Q4 | $6.82M | Buy |
579,217
+89,644
| +18% | +$1.1M | ﹤0.01% | 3119 |
|
|
2021
Q3 | $5.58M | Buy |
489,573
+65,877
| +16% | +$858K | ﹤0.01% | 3265 |
|
|
2021
Q2 | $5.9M | Sell |
423,696
-1,465
| -0.3% | -$22.3K | ﹤0.01% | 3186 |
|
|
2021
Q1 | $7.87M | Sell |
425,161
-134,049
| -24% | -$2.74M | ﹤0.01% | 2769 |
|
|
2020
Q4 | $9.88M | Buy |
559,210
+444,853
| +389% | +$7.81M | ﹤0.01% | 2481 |
|
|
2020
Q3 | $1.75M | Buy |
114,357
+30,229
| +36% | +$568K | ﹤0.01% | 3656 |
|
|
2020
Q2 | $2.14M | Buy |
84,128
+61,431
| +271% | +$1.28M | ﹤0.01% | 3409 |
|
|
2020
Q1 | $351K | Buy |
22,697
+9,154
| +68% | +$143K | ﹤0.01% | 4413 |
|
|
2019
Q4 | $150K | Sell |
13,543
-45,091
| -77% | -$392K | ﹤0.01% | 4975 |
|
|
2019
Q3 | $499K | Buy |
58,634
+44,601
| +318% | +$493K | ﹤0.01% | 4452 |
|
|
2019
Q2 | $190K | Sell |
14,033
-3,436
| -20% | -$53.3K | ﹤0.01% | 4809 |
|
|
2019
Q1 | $315K | Buy |
+17,469
| New | +$337K | ﹤0.01% | 4611 |
|
|
2018
Q3 | – | Sell |
-90,090
| Closed | -$1.56M | – | 5699 |
|
|
2018
Q2 | $1.56M | Buy |
+90,090
| New | +$1.63M | ﹤0.01% | 3784 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
VPM
VCM
Goldman Sachs's KNSA Position: Q1 2026 in Review
Goldman Sachs reduced its Kiniksa Pharmaceuticals (KNSA) stake by 79% in Q1 2026, selling an estimated $29M and leaving 174,901 shares worth $8.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3204.
Goldman Sachs first reported a position in KNSA in Q2 2018 and has held it in 29 quarters since. The position peaked at $34.2M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.
- Goldman Sachs held 174,901 shares of Kiniksa Pharmaceuticals worth $8.42M as of Q1 2026.
- Goldman Sachs sold 654,516 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $29M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3204 holding.
- Goldman Sachs first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
- Goldman Sachs's Kiniksa Pharmaceuticals position peaked at $34.2M in Q4 2025.
- 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.